S

Stryker

Manufactures orthopedic and surgical medical devices

Territory Sales Manager - Neurovascular

Full-TimeUpdated on 10/23/2026
£38.6k - £64.3k/yr
Mid
Bachelor's
London, UK
In PersonField-based, with regular travel across the UK and Ireland; up to 80% travel and occasional evening/weekend events.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree in Life Sciences, Radiography, or Biomedical Engineering, or equivalent work experience.
  • Existing experience in a medical sales environment.
  • Strong training, presentation and communication skills to engage clinicians, theatre staff and hospital leadership.
  • Ability to travel and work independently in a field role, with strong time-management, self-motivation and prioritisation.
  • Familiarity with the NHS system, procurement processes and budget environment in UK hospitals is advantageous.
  • Collaborative mindset with cross-functional work experience, such as sales, marketing or clinical education.
  • A full, clean driving licence.
Responsibilities
  • Achieve sales results in line with the annual sales target for the Flow Diverter, Intra-saccular and Coil portfolios.
  • Provide expert clinical support on interventional neurovascular procedures.
  • Act as the subject matter expert for the HEM portfolio, including anatomy, imaging, device usage, workflow optimisation and patient pathway improvement.
  • Support live cases as required, in-lab or in hybrid theatres, assisting with device set-up, optimal technique and operator training.
  • Design and deliver education programmes, workshops and simulation training for cross-functional hospital teams, in hospitals or training centres.
  • Develop training materials and support accreditation and competency programmes aligned with Stryker’s SKILL and StrokEnomics programmes.
  • Mentor internal staff and external stakeholder groups to enhance knowledge of stroke pathways, neurovascular devices and workflow best practice.
  • Partner with territory sales and marketing to develop and implement growth plans for key HEM accounts in the UK and Ireland.
  • Identify and engage key opinion leaders, clinical champions and stroke network leads, building relationships to shape clinical adoption and practice patterns.
  • Monitor the competitor landscape, clinical evidence and hospital workflow changes, and provide insights to Business Unit and Marketing teams.
  • Support case evaluations, trials, device introductions and account-level business reviews.
  • Ensure educational, training and device support activities align with better patient outcomes and hospital efficiency.
  • Work within regulatory, ethical and compliance frameworks, including UK/EU medical device regulations and NHS procurement frameworks.
  • Share clinical and economic insights through StrokEnomics to help hospitals and stroke networks make informed, sustainable decisions.
Desired Qualifications
  • Experience in an interventional neurovascular, peripheral, pulmonary or cardiac environment, or with hospital medical devices focused on neurovascular care or stroke.
  • Previous medical device experience in neurovascular or stroke markets.
  • Experience providing clinical support in live interventional cases, such as in an interventional radiology or neuroradiology theatre.

About the company

Stryker makes medical devices for hospitals, surgical centers and emergency responders, spanning joint implants, surgical instruments and patient transport equipment. Its Mako platform assists surgeons with joint replacement, while its neurotechnology products support brain and spine procedures and stroke treatment. Clinicians use its equipment during surgery and emergency care, and the company earns money by selling implants, disposable products and capital equipment through direct sales teams and distributors. The business also supplies training and technical support for healthcare providers using its devices. Stryker was founded in 1941 and is headquartered in Portage, Michigan.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kalamazoo, Michigan

Founded

1941

Get referred to Stryker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand supports growth: July 2026 Stryker results show organic sales rose 9%, with reported sales reaching $6.6 billion.
  • Service extends equipment sales: Stryker's ProCare contracts bundle preventive maintenance, repairs and original manufacturer parts.
  • Relocation is available for Worcester technicians: Stryker's live transport service opening also lists 12 paid holidays.

What critics are saying

  • Operational failures reach customers: March 2026 cyberattack disrupted Stryker's ordering, manufacturing and shipping.
  • Older implants retain legal exposure: Stryker's recall estimates include Rejuvenate, LFIT V40 and legacy Wright hip products.
  • Field service demands travel: Stryker's northern Minnesota opening lists 80% travel plus evening or weekend call.

What makes Stryker unique

  • Mako combines imaging and physical guidance: Stryker uses CT-based planning and haptic boundaries during hip replacement.
  • Discarded devices return to service: Stryker's Sustainability Solutions reprocesses medical equipment for hospitals across the U.S. and Canada.
  • Transport extends its technology outside hospitals: Stryker's Power-LOAD supports stretchers while loading and unloading ambulances.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical & prescription plans
  • Supplemental health benefits
  • Flexible Spending accounts
  • Employee Assistance Program
  • Short-term & long-term disability
  • Tuition reimbursement
  • 401(k) plan
  • Employee Stock Purchase Plan

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 21st, 2026
P&G and Stryker: two dividend stocks to hold for decades

Procter & Gamble and Stryker are two dividend stocks suited to long-term holders, according to the article. Both sell products people need in any economy. P&G has raised its dividend for 70 consecutive years. In fiscal 2026, it posted net sales of about $87 billion, up 3%, and net earnings of $16.1 billion. It returned more than $15 billion to shareholders, including $10.2 billion in dividends. Organic sales and core earnings per share each grew just 1%. Stryker has raised its dividend for more than three decades. Second-quarter 2026 revenue rose 9.4% to $6.6 billion, and adjusted earnings per share climbed 17.9% to $3.69. Demand should gain from an ageing US population, though recalls, acquisition costs, and hospital spending pressures remain risks.

Yahoo Finance
Oct 14th, 2026
Stryker wins FDA clearance for Sonopet 3 ultrasonic bone and tissue removal platform

Stryker has received US Food and Drug Administration (FDA) 510(k) clearance for Sonopet 3, the latest version of its ultrasonic bone and soft tissue removal platform. The company announced the news on October 14, 2026. Stryker developed the platform with input from hundreds of surgeons. It offers more power, precision and versatility, along with two technologies: RISE, which connects the surgical workflow, and Pulse Control, which helps regulate the resection of hard and soft tissues. "They told us they wanted more power, improved ergonomics and enhanced integration," said Mitch Foley, vice president and general manager of Stryker's Neurosurgical business. The first clinical cases are expected to begin in October. A full commercial launch is planned for later this fall.

Yahoo Finance
Oct 12th, 2026
Stryker shares fall 20% in six months despite 9.2% organic growth and $25.84B revenue

Stryker (NYSE:SYK) shares have fallen 20% over the past six months to $277.82, while the S&P 500 gained 12.8%. The medical device maker develops orthopedic, surgical, neurotechnology, and patient care products that reach over 150 million patients a year. Organic revenue, which excludes acquisitions, divestitures, and currency swings, grew an average of 9.2% year-on-year over the past two years. That suggests Stryker can expand without costly acquisitions. Revenue over the past 12 months was $25.84 billion. Its scale gives it leverage with suppliers in a heavily regulated, competitive market. Free cash flow margin rose 6.5 percentage points over five years to 18.2% for the trailing 12 months. After the drop, the stock trades at 17.4× forward earnings.

Seeking Alpha
Oct 12th, 2026
Stryker to invest $400M in CMR Surgical, with option to buy the robotics maker outright

Stryker announced a $400 million (£300 million) preferred equity investment in CMR Surgical on Monday. The money will support innovation and global expansion of CMR's Versius surgical robotics portfolio. The deal also gives Stryker an exclusive option to acquire 100% of CMR Surgical.

PR Newswire
Oct 5th, 2026
Stryker launches Mako 4 SmartRobotics in India after 2.5M procedures globally

Stryker has launched Mako 4 SmartRobotics in India, introducing the fourth generation of its robotic-arm assisted technology for joint replacement procedures. The system combines patient-specific planning, robotic technology, and haptic guidance for total knee, partial knee, and total hip applications. Mako 4 uses 3D CT-based planning with AccuStop haptic technology to support surgeons in planning and executing procedures according to individual patient anatomy. The platform provides real-time intraoperative guidance for greater precision during joint replacement procedures. The global Mako platform has supported more than 2.5 million procedures across 47 countries. Aman Rishi, Stryker's vice president and general manager for India, said the launch aims to raise the standard of care and expand access for joint replacement patients nationwide.